Literature DB >> 3974572

Comparison of the actions of carbamate anticholinesterases on the nicotinic acetylcholine receptor.

S M Sherby, A T Eldefrawi, E X Albuquerque, M E Eldefrawi.   

Abstract

Neostigmine (Neo), pyridostigmine (Pyr), and physostigmine (Phy) at low concentrations inhibited acetylcholine (ACh) esterase, thereby indirectly potentiating ACh enhancement of [3H]perhydrohistrionicotoxin (H12-HTX) binding to the channel sites of the nicotinic ACh receptor of Torpedo membranes. However, at higher concentrations, they inhibited ACh action due to their direct binding to the ACh receptor. They displaced binding of [3H]ACh and 125I-alpha-bungarotoxin (alpha-BGT) to the receptor sites with the following order of decreasing potency: Neo greater than Phy greater than Pyr. Furthermore, Neo and Pyr potentiated [3H] H12-HTX binding to the receptor's channel sites. Preincubation of ACh receptors with any of the three carbamates reduced the rate of binding of 125I-alpha-BGT and increased the potency of carbamylcholine in inhibiting 125I-alpha-BGT binding, suggesting that the three carbamates act as partial agonists and potentiate receptor desensitization. Although none of the three carbamates inhibited [3H]H12-HTX binding to the receptor's closed channel conformation, only Phy was a potent inhibitor of [3H]H12-HTX binding to the carbamylcholine-activated conformation. The potency of Phy was not due to the absence of positive charge since Phy methiodide acted similarly. The data suggest that the major action of the three carbamates at nicotinic cholinergic synapses is inhibition of ACh-esterase. Their interactions with the nicotinic ACh receptor are with its "receptor" as well as allosteric "channel" sites, but they differ in their effects. Neo and Pyr act mainly as partial agonists, while Phy is mostly an inhibitor of the channel in the activated receptor conformation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974572

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  The effect of chronic neostigmine treatment on channel properties at the rat skeletal neuromuscular junction.

Authors:  M Gwilt; D Wray
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

2.  Activation and block of the adult muscle-type nicotinic receptor by physostigmine: single-channel studies.

Authors:  Julius Militante; Bei-Wen Ma; Gustav Akk; Joe Henry Steinbach
Journal:  Mol Pharmacol       Date:  2008-06-03       Impact factor: 4.436

3.  Bispyridinium (oxime) compounds antagonize the "ganglion blocking" effect of pyridostigmine in isolated superior cervical ganglia of the rat.

Authors:  C Schlagmann; H Ulbrich; J Remien
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

4.  Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum.

Authors:  P B Clarke; M Reuben; H el-Bizri
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

Review 5.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

6.  Physostigmine and galanthamine bind in the presence of agonist at the canonical and noncanonical subunit interfaces of a nicotinic acetylcholine receptor.

Authors:  Ayman K Hamouda; Tilia Kimm; Jonathan B Cohen
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

Review 7.  Pathophysiological effects of synthetic derivatives of polymeric alkylpyridinium salts from the marine sponge, Reniera sarai.

Authors:  Marjana Grandič; Robert Frangež
Journal:  Mar Drugs       Date:  2014-04-30       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.